In contrast to the chemotherapeutic drug mitoxantrone (MTX), 3,4‐DC alone failed to reduce the infiltration of tumor by regulatory T cells (Tregs) and to improve the CD8+/Treg ratio, yet tended to improve these MTX effects (Fig 8B–E). The gene discussed is CD8A; the disease is neoplasm.